Musk releases "mass production timetable," brain-computer interface stocks surge; is the commercialization turning point here?

```

As Elon Musk has explicitly announced a mass production schedule for brain-computer interface devices, this cutting-edge field is rapidly transitioning from laboratory scientific exploration to commercial implementation. The industry may soon reach a critical turning point—from "medical experimental products" to "mass consumer goods."

On the first trading day of A-shares in 2026, the brain-computer interface sector performed strongly. Beiyikang hit the 30CM upper limit, and several other stocks such as Sanbo Brain, Xiangyu Medical, Meihai Medical, Aipeng Medical, Chengyitong, and Weisi Medical reached the 20CM upper limit. Market capital is showing extremely high expectations for the commercialization prospects of brain-computer interfaces.

The direct trigger for this rally was Neuralink’s latest development. On January 1 local time, Musk announced on social media that Neuralink would start mass production of its brain-computer interface devices in 2026 and advance a nearly fully automated surgical solution. At the same time, Merge Labs, supported by OpenAI CEO Sam Altman, is spinning off independently, focusing on a new technological pathway using ultrasound to read brain activity. The moves by these two tech giants indicate that brain-computer interfaces are shifting from single scientific experiments to diverse commercial competition.

This series of developments not only verifies the feasibility of the technology, but also triggers a market reassessment of the broad application prospects of brain-computer interfaces in medical rehabilitation, AI interconnection, and humanoid robot collaboration. Several brokerages point out that, driven by both technological breakthroughs and favorable policies, the industry is in a period of high growth potential. Investors should closely follow leading companies with core technology and regulatory barriers, as well as genuine market demand that can "weed out the false and preserve the true."

Mass Production Expectations Realized, Major Surgical Innovation

Open Source Securities stated in its latest research report that Neuralink’s mass production forecast and automated surgery solution are both milestones. This not only signifies the transition of brain-computer interfaces from "medical experimental tools" to "popularizable products," but also lays a foundation for future collaborative applications with Tesla’s Optimus humanoid robot.

Neuralink’s technological progression path is now clearly defined. Currently, 12 people globally have been implanted with Neuralink devices, with a cumulative usage time of more than 15,000 hours. The first recipient, Noland Arbaugh, can now type and play games with his mind. According to Neuralink’s plan, the number of electrode channels will rise to 3,000 in 2026, along with clinical testing for blindness restoration; by 2028, the goal is for a single device to have over 25,000 electrode channels and achieve full-brain region connectivity.

According to a report from Morgan Stanley analyst Adam Jonas' team, Neuralink is currently valued at about $9 billion, and its commercialization process is significantly accelerating. The report predicts that in the U.S. market alone, the potential total market size for brain-computer interface implants could reach $80 billion by 2035, mainly covering the treatment of neurological diseases such as ALS and stroke.

China-U.S. Competition, Diverse Technical Routes

Currently, competition is fierce in the global brain-computer interface field, presenting a diversified technological competition landscape. In terms of clinical trials and approvals, both China and the U.S. are in clinical stages for invasive technologies. The U.S. is progressing faster in semi-invasive areas, while in China, the non-invasive sector is thriving with a variety of approaches.

Domestic companies have made significant progress in specific areas. BrainTiger Technology, a domestic invasive brain-computer interface company, independently developed a 256-channel high-throughput implanted flexible brain-computer interface, marking China's achievement of a world-leading level in the field. In the non-invasive sector, QiangNao Technology launched a consumer-grade smart sleep aid device, and companies like Chengyitong and Xiangyu Medical plan to apply the technology in anesthesia monitoring and medical rehabilitation.

CITIC Construction Investment believes that there is no absolute advantage or disadvantage between non-invasive and invasive brain-computer interfaces. The key lies in leveraging national policy support and identifying the "real brain-computer interface" with genuine needs. China's brain-computer interface technological research stands relatively at the forefront globally, and its manufacturing industry chain has notable advantages, offering hope for cultivating world-leading brain-computer interface enterprises.

Human-Machine Collaboration: From Medical Necessity to the Ultimate AI Form

Besides being a necessity in the medical field, the brain-computer interface is seen as a key to unlocking the ultimate form of human-machine collaboration.

Open Source Securities analysis believes that the brain-computer interface industry is expanding from medical necessities to applications in AI, robotics, and other fields. Musk has clearly stated that as Neuralink technology upgrades, it may enable remote control of the Optimus robot via thought alone, forming the ultimate ecosystem of "human brain + robot."

According to data from Precedence Research, it is expected that the global brain-computer interface market size will grow to about $12.4 billion by 2034, with a compound annual growth rate of 17% from 2025 to 2034. Morgan Stanley goes even further and predicts that the market size will jump to $320 billion by 2045.

CITIC Construction Investment points out that brain-computer interfaces are both a medical and technology investment. In the short term, motor decoding products are expected to be commercialized first for rehabilitation of paralysis and ALS. In the long term, if human abilities can be enhanced and merged with AI and robotics, a trillion-dollar market space could open up.

Policy Support and Trillion-Dollar Market Prospects

Continuous policy support has provided a solid foundation for industry development.

The brain-computer interface has been included as a future industry in China's 15th Five-Year Plan. The 2025 special implementation opinion sets a goal of technological breakthroughs by 2027 and for industry strength to reach the world’s forefront by 2030. In addition, the National Healthcare Security Administration has issued a statement requiring the facilitation of code applications for innovative medical consumables like brain-computer interface products, solving the "last mile" problem for hospital adoption; the industry standard "Medical Device Terminology Using Brain-Computer Interface Technology" from the National Medical Products Administration will also be officially implemented in 2026.

Tianfeng Securities suggests that investors should focus on companies with a "policy + device + algorithm + clinical" closed loop, as well as leading companies with advantages in device development and algorithm optimization. Also, watch for the development of regional industrial clusters, such as Guangdong Province, which has many brain-computer interface companies, and Beijing, which has the highest number of patent applications.

In the long run, leading companies will form dual barriers of technology and compliance. CITIC Construction Investment suggests focusing on companies with core patents, strong R&D capabilities, and compliance with strict medical regulatory requirements, as well as those that can leverage existing resources to accelerate the development of their brain-computer interface business through synergy with traditional operations.

Risk Warning and DisclaimerThe market has risks, investment needs caution. This article does not constitute personal investment advice, nor does it take into account the individual investment objectives, financial situation, or needs of any particular user. Users should consider whether any opinions, views, or conclusions in this article suit their particular circumstances. Any investment based on this is at your own risk. ```